Core Insights - Lexaria Bioscience Corp. has extended its Material Transfer Agreement (MTA) with PharmaCO until April 30, 2026, to allow for the review of data from an Australian study [2][3] - The MTA enables continued collaboration and strategic planning discussions between Lexaria and PharmaCO's clinical development team [2] - Lexaria's DehydraTECH™ technology aims to enhance drug delivery through oral administration, improving bio-absorption and reducing side effects [4] Summary by Sections Material Transfer Agreement Update - The MTA originally signed on September 4, 2024, has been extended to accommodate PharmaCO's review of Lexaria's Australian study data [2] - This extension allows both parties to maintain their relationship and keep the temporary exclusive license active [2] Pre-Clinical Studies and Future Expectations - Initial pre-clinical studies examining pharmacokinetics in animals have been completed [3] - Lexaria is awaiting PharmaCO's review of safety, pharmacokinetic, and efficacy data from its independent Australian human clinical study, with final results expected by the end of Q4 2025 [3] About Lexaria and DehydraTECH - DehydraTECH™ is a patented drug delivery platform that enhances the absorption of various drugs through oral delivery [4] - Lexaria holds a strong intellectual property portfolio with 54 patents granted and additional patents pending globally [4]

Core Insights - Lexaria Bioscience Corp. has engaged a global life science business development advisory firm to enhance its business development activities and identify collaborative opportunities in the pharmaceutical and biotechnology sectors [3][4][6] - The company has been awarded four new patents, expanding its intellectual property portfolio and supporting its strategic R&D programs in various therapeutic areas [9][10] Business Development - Lexaria has validated its DehydraTECH technology for applications in diabetes control, weight loss, hypertension, seizure disorders, anti-viral treatments, and hormone replacement [2] - The recent equity financing raised $4.0 million, enabling Lexaria to expand its strategic outreach and R&D activities into 2026 [4][7] - The engagement of the advisory firm is expected to facilitate new outreach activities and strengthen business connections within the pharmaceutical industry [3][6] Research and Development - Lexaria's R&D programs are designed to evolve alongside its business development efforts, with a focus on building strategic connections in the pharmaceutical and biotechnology sectors [5][6] - The company anticipates results from a Phase 1b Australian study in the GLP-1 sector, which is expected to demonstrate patient safety and efficacy with DehydraTECH processing [8] - The newly awarded patents cover therapeutic applications in diabetes, hypertension, seizure disorders, and antiviral treatments, enhancing the company's R&D capabilities [9][10]

Core Points - Lexaria Bioscience Corp. has closed a registered direct offering of 2,666,667 shares at a price of $1.50 per share, raising approximately $4.0 million before expenses [1][3] - The company also issued unregistered warrants for the purchase of an equal number of shares at an exercise price of $1.37, which are immediately exercisable and expire in five years [1][2] - The financing aims to enhance Lexaria's options for its 2026 R&D and business development plans, focusing on executing research initiatives that drive intellectual property and shareholder value [2] Financial Details - The gross proceeds from the offering were approximately $4.0 million, which will be used for working capital and general corporate purposes [3] - The shares were offered under a "shelf" registration statement effective since January 30, 2025, and the offering was conducted in compliance with SEC regulations [4] Warrants and Securities - The warrants were issued in a private placement and are not registered under the Securities Act, limiting their sale in the U.S. without an effective registration statement [5] - The company emphasizes that the offering does not constitute an offer to sell or solicit any offers to buy the securities in jurisdictions where such actions would be unlawful [6] Technology and Intellectual Property - Lexaria's DehydraTECH™ platform enhances drug delivery through oral administration, improving bio-absorption and reducing side effects [7] - The company holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide [7]

Core Viewpoint - Lexaria Bioscience (NASDAQ:LEXX) is experiencing a decline in stock price following the announcement of a direct offering of 2,666,667 shares at a price of $1.50 per share, which is expected to generate gross proceeds of approximately $4.0 million [1] Group 1 - The company announced a sale of 2,666,667 shares with a par value of $0.001 per share [1] - The offering price is set at $1.50 per share [1] - Gross proceeds from the offering are anticipated to be around $4.0 million [1]

Core Points - Lexaria Bioscience Corp. has entered into a definitive agreement to sell 2,666,667 shares of common stock at a price of $1.50 per share in a registered direct offering [1] - Concurrently, the company will issue unregistered warrants to purchase an additional 2,666,667 shares at an exercise price of $1.37 per share, which will be immediately exercisable and expire in five years [1] - The total gross proceeds from the offering are expected to be approximately $4.0 million before deducting fees and expenses [2] Offering Details - The shares are being offered under a "shelf" registration statement that was declared effective by the SEC on January 30, 2025 [3] - The offering is made only by means of a prospectus, which will be filed with the SEC and available on their website [3] - The warrants are issued in a private placement and have not been registered under the Securities Act, limiting their sale in the U.S. [4] Company Overview - Lexaria's DehydraTECH™ technology enhances drug delivery through oral administration, improving bio-absorption and reducing side effects [6] - The company holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide [6]

Key Points - Top KingWin Ltd (NASDAQ: WAI) shares increased by 87.4% to $5.92 in pre-market trading after announcing a sales contract with Walker Times International for 10,000 units of TK-D2C AI Robots [1] - MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) saw a significant rise of 242% to $4.96 in pre-market trading due to plans to double the installation of its Authentication Device "Orb" to 200 stores in collaboration with "World" [5] - New Era Energy & Digital, Inc. (NYSE: NUAI) surged 37.6% to $1.90 in pre-market trading after a previous 50% increase [5] - Datavault AI Inc. (NASDAQ: DVLT) gained 33% to $1.11 in pre-market trading after securing a $150 million investment in Bitcoin to build a supercomputer [5] - Harrison Global Holdings Inc. (NASDAQ: BLMZ) increased by 28.3% to $0.2288 in pre-market trading [5] - Lexaria Bioscience Corp. (NASDAQ: LEXX) rose 28.1% to $1.96 in pre-market trading after ending its "Capital on Demand" Sales Agreement with JonesTrading Institutional Services LLC [5] - Safety Shot, Inc. (NASDAQ: SHOT) gained 14.8% to $0.2868 in pre-market trading following a partnership with Monarq Asset Management [5] - Diginex Limited (NASDAQ: DGNX) jumped 13.6% to $15.00 in pre-market trading after a previous decline of 16% [5] - GLOBALFOUNDRIES Inc. (NASDAQ: GFS) increased by 9.9% to $36.09 in pre-market trading [5] - American Rebel Holdings, Inc. (NASDAQ: AREB) surged 9.7% to $1.13 after announcing a 1-for-20 reverse stock split [5] - Kuke Music Holding Limited (NYSE: KUKE) dipped 30.5% to $0.8200 after acquiring a controlling interest in Naxos Music Group [5] - Wellgistics Health, Inc. (NASDAQ: WGRX) fell 24.3% to $0.7598 after announcing a $5 million public offering [5] - Wolfspeed, Inc. (NYSE: WOLF) shares decreased by 24% to $1.41 after a decline of around 17% on Thursday [5] - Concentrix Corporation (NASDAQ: CNXC) declined 20.5% to $43.73 after reporting worse-than-expected third-quarter adjusted EPS results and cutting FY25 adjusted EPS guidance [5] - DarioHealth Corp. (NASDAQ: DRIO) fell 18.9% to $11.10 after a previous jump of 44% following a strategic review [5] - N2OFF, Inc. (NASDAQ: NITO) declined 13.7% to $4.75 after stockholders approved the acquisition of MitoCareX Bio [5] - Legacy Education Inc. (NYSE: LGCY) fell 13.3% to $10.68 after reporting worse-than-expected fourth-quarter EPS results [5] - Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) dipped 9.5% to $20.12 in pre-market trading [5] - Pharming Group N.V. (NASDAQ: PHAR) fell 9.1% to $13.45 in pre-market trading [5] - Kingsoft Cloud Holdings Limited (NASDAQ: KC) decreased by 7.5% to $16.15 after announcing the pricing of an upsized HK$2,802 million offering of new shares [5]

Core Insights - Several small-cap stocks experienced significant gains in after-hours trading due to corporate updates, clinical developments, and strategic shifts Company Summaries MEDIROM Healthcare Technologies Inc. (MRM) - Shares surged 282.8% to $5.55 after announcing plans to double the installation of its biometric authentication device "Orb" to 200 stores in collaboration with "World" [2] - Closed at $1.45 during regular trading, down 7.05%, with a trading volume of over 31.5 million shares [3] - The stock has a 52-week range of $0.34 to $5.30, highlighting the scale of its overnight move [3] Lexaria Bioscience Corp. (LEXX) - Shares rose 45.75% to $2.23 following renewed interest in its DehydraTECH drug delivery platform, which enhances GLP-1 drug delivery [4] - Closed at $1.53, up 7.75%, with a volume exceeding 7.5 million shares [5] - The stock's 52-week range is $0.775 to $3.392, with Thursday's close near the midpoint [5] Safety Shot, Inc. (SHOT) - Shares increased 12% to $0.28 after announcing a partnership with Monarq Asset Management to manage its BONK Holdings Treasury [6] - Closed at $0.25, down 9.06%, with a trading volume of over 15.4 million shares [7] - The stock has a 52-week range of $0.23 to $1.35, with the after-hours price near the lower end [7] Aquestive Therapeutics, Inc. (AQST) - Shares rose 11.41% to $5.86 following favorable regulatory news regarding its oral epinephrine candidate, Anaphylm [8] - Closed at $5.26, down 2.95%, with a volume of over 3.6 million shares [9] - The stock's 52-week range is $2.12 to $6.00, with the after-hours price near the upper end [9] Ovid Therapeutics Inc. (OVID) - Shares increased 4.26% to $1.47 after reaching a 52-week high during regular trading, driven by progress in its neurological pipeline [10] - Closed at $1.41, up 0.71%, with a trading volume of over 2.4 million shares [11] - The stock has a 52-week range of $0.2430 to $1.47, with Thursday's close at the top end of its recent performance band [11]

Core Insights - The study conducted by Lexaria Bioscience Corp. indicates that the DehydraTECH processing of semaglutide enhances its brain biodistribution compared to conventional formulations, potentially improving safety and efficacy [1][3][6] Study Findings - The primary objective of the study was to assess whether DehydraTECH processing significantly improves the biodistribution of semaglutide [2] - The DehydraTECH-FTS composition showed a higher apparent trend in brain biodistribution across all tested doses, with the 5mg DehydraTECH-FTS achieving greater brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent [3][5] - Fluorescent imaging revealed that all three DehydraTECH doses tested had higher fluorescence in key brain regions compared to naïve and vehicle groups, while only the highest dosage of Rybelsus® surpassed these groups [5] Mechanism and Implications - The study suggests that enhanced brain biodistribution may be linked to the pharmacodynamic performance of GLP-1 drugs, which are known to interact with brain neurochemistry [6][7] - Semaglutide's ability to regulate body weight through GLP-1 receptor activation in the brain could lead to appetite suppression without common side effects like nausea [6] - Lexaria's findings may support the development of safer and more effective GLP-1 drugs in the future [8] Research Methodology - The preclinical pilot study involved Sprague Dawley rats and utilized non-invasive whole-body imaging and ex vivo organ analysis to evaluate the biodistribution of oral semaglutide [9][12] - A total of 25 male rats were used, with 22 allocated for dosing and 3 as untreated controls, examining both DehydraTECH and Rybelsus® equivalent compositions [12][13] Technology Overview - DehydraTECH is a patented drug delivery platform that enhances the absorption and effectiveness of various drugs, including those that cross the blood-brain barrier [14]

Core Viewpoint - Lexaria Bioscience Corp. will participate in the 27th Annual H.C. Wainwright Global Investment Conference from September 8th to September 10th, 2025, highlighting its innovative drug delivery technology, DehydraTECH [1][3]. Company Overview - Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on improving the way drugs enter the bloodstream through oral delivery [1][3]. - The company operates a licensed in-house research laboratory and holds a strong intellectual property portfolio with 50 patents granted and additional patents pending worldwide [3]. Technology Highlights - DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform that enhances bio-absorption, reduces side effects, and improves drug delivery across the blood-brain barrier [3].

Core Insights - Lexaria Bioscience Corp. has achieved a significant milestone in its Phase 1b GLP-1 study in Australia, completing the last patent last visit (LPLV) [1][2] - The study involved 126 participants and focused on evaluating various DehydraTECH formulations against a control arm using Rybelsus® [4][6] - Interim results have shown positive outcomes, particularly in safety and tolerability compared to the control arm, with a notable reduction in gastrointestinal adverse events [3] Study Details - The study included 24-25 overweight, obese, pre- or type 2 diabetic patients in each of the five study arms, with a total of 126 participants [4] - All doses were administered orally, with no injections involved, as Lexaria aims to shift the standard of care towards oral delivery [4] - The study arms included proprietary formulations of DehydraTECH-CBD and DehydraTECH-processed semaglutide, with the fifth arm evaluating DehydraTECH-tirzepatide [5][6][7] Future Objectives - Lexaria plans to release the final results of the study in the fourth quarter of 2025 [9] - The company is currently engaged in data analysis and sample processing, with a comprehensive database being developed [2] Technology Overview - DehydraTECH™ is Lexaria's patented drug delivery technology that enhances the bio-absorption of drugs through oral delivery, aiming to reduce side effects and improve efficacy [10] - The company holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide [10]